Danske Bank A S purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,185 shares of the company's stock, valued at approximately $24,840,000. Danske Bank A S owned approximately 0.06% of IDEXX Laboratories as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Elyxium Wealth LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $3,666,459,000. State Street Corp grew its position in shares of IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock valued at $2,473,817,000 after acquiring an additional 138,956 shares during the period. J. Stern & Co. LLP grew its position in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock valued at $1,795,072,000 after acquiring an additional 2,642,200 shares during the period. Geode Capital Management LLC increased its stake in shares of IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock valued at $1,749,380,000 after purchasing an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of IDEXX Laboratories by 13.8% in the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock valued at $1,016,296,000 after purchasing an additional 181,955 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.
IDEXX Laboratories Trading Up 1.6%
IDXX stock opened at $562.20 on Thursday. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The business's 50-day moving average is $560.33 and its 200 day moving average is $577.89. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.29 billion, a price-to-earnings ratio of 39.54, a PEG ratio of 2.95 and a beta of 1.54.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on IDXX. Barclays lowered their price target on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. UBS Group lifted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $747.00.
View Our Latest Stock Report on IDEXX Laboratories
IDEXX Laboratories Company Profile
(
Free Report)
IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
